OptiBiotix Health (OPTI.L) Stock Price

OptiBiotix Health Price

LSE·CLOSED
0.06
​
Market closed

Revenue has compounded at 22.0% per year over the past 14 years to 1.17 M GBP. Earnings per share have grown at 4.9% per year over the last 5 years. OptiBiotix Health's net margin stands at -333.6%, down from 282.9% several years earlier.

OptiBiotix Health stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

OptiBiotix Health business model & stock analysis

OptiBiotix Health Plc is a British company founded in 2012 that focuses on the development and marketing of pre- and probiotic products. The company's goal is to improve the health and well-being of people around the world. OptiBiotix Health has developed a unique business model based on identifying new applications for existing nutrients and probiotic bacteria. The company works closely with leading academic institutions to develop innovative technologies and products based on scientific knowledge and clinical studies. An important division of the company is weight management products. OptiBiotix Health has developed a promising approach based on the identification of bacterial strains that can reduce the growth of fat cells and improve metabolism in the body. These bacteria can be found in products such as "SlimBiome," "GoFigure," and "CholBiome." Another area covered by OptiBiotix Health is gastroenterology. The Bonne Santé products include vitamin-rich, fiber-rich, and lactic acid bacteria-rich foods and beverages that keep the digestive system healthy and promote well-being. By using probiotics and prebiotics, the company can also offer products for people with digestive disorders and conditions such as irritable bowel syndrome. OptiBiotix Health also has a health monitoring and diagnostics department that focuses on the discovery of biomarker-based tests. These tests can be used to detect specific diseases and predict the course of diseases. Some of the key products being developed here are "SweetBiotix" and "CardioBiotix." These products aim to reduce the risk of type 2 diabetes and cardiovascular diseases as part of the life science portfolio. OptiBiotix Health's products are distributed worldwide. The company has various agreements with leading manufacturers and distribution partners in Europe, Asia, and North America. In addition to marketing its own products, the company also offers technologies and expertise for the development and marketing of probiotic and prebiotic products. OptiBiotix Health has solidified its successes by winning a number of awards. In 2019, the company won the Health Investor award for "Pharma/Technology Deal of the Year" for its partnership with Seed Health LLC, and in 2020, its online group "OptiBiotix Health PLC Forum" was nominated for the "Best Informative Forum Award" at the British Online Awards. The vision of OptiBiotix Health is to improve the health and well-being of people by developing and marketing innovative and effective products and technologies. The company is committed to scientific thinking and continuous innovation to fully harness the potential of probiotic and prebiotic products.

Frequently asked questions about OptiBiotix Health

OptiBiotix Health PLC is a company focused on developing and commercializing microbial strains and compounds, which have the potential to impact human health. Their business model revolves around identifying and understanding specific health conditions and using science-based solutions to develop innovative and effective products. OptiBiotix Health PLC aims to address various health concerns, including obesity, diabetes, and cholesterol management, by utilizing their expertise in the microbiome and actively collaborating with commercial partners. By leveraging cutting-edge research and technologies, they strive to provide evidence-based and clinically-supported solutions to improve human health and well-being.

OptiBiotix Health PLC is primarily active in the healthcare and biotechnology industries.

The main competitors of OptiBiotix Health PLC in the market are other companies operating in the field of probiotics and microbiome-based health and wellness products. These competitors include established players like Probi AB, DuPont Nutrition & Biosciences, and Chr. Hansen Holding A/S. With its innovative products and scientific approach, OptiBiotix Health PLC competes for market share in the rapidly growing global probiotics industry. By leveraging its proprietary technologies and research, OptiBiotix Health PLC aims to differentiate itself and carve a niche in the market.

OptiBiotix Health PLC is a UK-based company focused on developing and commercializing innovative products that target human microbiome modulation. Founded in 2014, OptiBiotix has quickly gained recognition in the field of science-driven microbiome research. The company collaborates with leading academic institutions and industry partners to develop microbiome-based therapeutics, probiotics, and functional ingredients. OptiBiotix's proprietary technology platform provides a solid foundation for advancing their product pipeline, which includes well-researched applications in weight management, cholesterol reduction, and cardiovascular health. These groundbreaking efforts, combined with relentless dedication to leading-edge research and development, have earned OptiBiotix a distinguished reputation in the microbiome and biotechnology sectors.

OptiBiotix Health PLC, a leading company in the healthcare industry, has achieved several significant milestones. Firstly, the company successfully developed and launched OptiBiotix's flagship product, SlimBiome®. This innovative weight management ingredient has gained immense popularity due to its effectiveness in promoting healthy weight loss. Moreover, OptiBiotix Health PLC has formed strategic partnerships with renowned companies and organizations. Collaborations with major players such as DSM, Tata Chemicals, and Seed Health have further expanded the company's reach and market presence. Additionally, OptiBiotix Health PLC has received numerous accolades and awards, recognizing its exceptional contributions to the health and wellness sector. These accomplishments reflect the company's commitment to providing quality products and driving advancements in the field of microbiome science. Overall, OptiBiotix Health PLC's achievements demonstrate its dedication to delivering innovative solutions for better health and its continuous efforts towards improving the well-being of individuals worldwide.

OptiBiotix Health PLC is primarily present in the United Kingdom, Europe, and the United States.

OptiBiotix Health PLC represents values focused on promoting health and wellbeing through innovative solutions. The company's corporate philosophy centers around scientific excellence, research-driven development, and collaboration with industry leaders. OptiBiotix Health PLC aims to improve people's lives by offering scientifically validated products that target and support gut microbiome modulation. With a strong emphasis on cutting-edge probiotic research and advanced microbiome science, OptiBiotix Health PLC is committed to delivering effective and evidence-based solutions to meet the growing demand for gut health enhancement.

7 analysts currently rate the OptiBiotix Health stock: 0 recommend buying, 3 holding and 4 selling.

Converted at the current exchange rate, the OptiBiotix Health share trades at 0.07 EUR (0.06 GBP).

The OptiBiotix Health share (OPTI.L) is listed on 3 stock exchanges, including: London (OPTI.L), Frankfurt (OB3.F).

OptiBiotix Health PLC is a biotechnology company based in the United Kingdom, specializing in the development and commercialization of dietary supplements and functional/probiotic premium compounds. The core business of OptiBiotix Health is the creation of proprietary products designed to improve the health and well-being of its customers. The company focuses on the development of prebiotics that support the body's natural gut bacteria to resolve digestive issues, strengthen the immune system, and reduce the risk of diseases, among other benefits. OptiBiotix Health's product range also includes probiotics that contain a high concentration of healthy bacteria. These products help protect and support digestion and promote positive gut health. The products are available in the form of supplements and can be found in the beverage and food industry, as well as in applications for animal husbandry. OptiBiotix Health has a comprehensive research and development department that continually works to explore new markets and applications. The company offers a product range of over 20 different products and collaborates with numerous customers in the food industry. The company also aims to develop innovative solutions for global health issues, such as new therapies to combat obesity, diabetes, and cholesterol levels, as well as optimize gut health. OptiBiotix Health operates based on B2B distribution partnerships and has agreements with many leading companies in the food and beverage industry. The partners use OptiBiotix Health's proprietary products in their own products and integrate them into their manufacturing process. The partners benefit from the patented premium compounds and can enhance their products accordingly. In addition to the B2B distribution partnerships, OptiBiotix Health has legal agreements with production companies to enable them to produce the products based on the unique and patented formulations. OptiBiotix Health examines all stages of the value chain to ensure that the high quality of the products is maintained even in the subordinate production steps. Overall, OptiBiotix Health PLC has developed an innovative business model by focusing on intensive research and the development of proprietary products. Together with a network of business partners and distribution channels, OptiBiotix Health is able to serve its market globally and enter into licensing agreements with many retailers.

The revenue cannot currently be calculated for OptiBiotix Health.

The profit cannot currently be calculated for OptiBiotix Health.

The P/E ratio cannot be calculated for OptiBiotix Health at the moment.

The P/S cannot be calculated for OptiBiotix Health currently.

The Eulerpool Quality Score for OptiBiotix Health is 5/10.

The ISIN of OptiBiotix Health is GB00BP0RTP38. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of OptiBiotix Health is A118S6. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of OptiBiotix Health is OPTI.L. The ticker symbol is used to trade OptiBiotix Health shares on the stock exchange.

Fair ValueTerminal
0.05 GBP
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
116,600.00 GBP
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
GBP
Initial public offering
Sep 9, 2011
ISIN
GB00BP0RTP38
Cusip
G6771U100
Sedol
BP0RTP3
Market capitalization
5.43 M GBPMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/S
P/Se
—
EV/EBIT
—
P/B Ratio
0.86
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-61.92 %
Last updated Nov 11, 2026, 4:51 AM

OptiBiotix Health Ticker

FRANKFURT · OB3.FLONDON · OPTI.LLONDON STOCK EXCHANGE · OPTI.L

OptiBiotix Health FIGI

OPTI:LN · BBG00217M8N1CMI1:PZ · BBG002266KY1OPTIGBX:EO · BBG006651R25OPTIGBX:XH · BBG006651R52OPTIGBX:XF · BBG006651R70OPTIGBX:XE · BBG006651R98OPTIGBX:XJ · BBG006651RB5OPTIGBX:XL · BBG006651RC4OPTIGBX:XG · BBG006651RD3OPTIGBX:XO · BBG006651RF1OPTIGBX:XS · BBG006651RK5OPTIGBX:XA · BBG006651RL4